Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2013 1
2014 1
2017 1
2021 2
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths.
Cortés-López M, Chamely P, Hawkins AG, Stanley RF, Swett AD, Ganesan S, Mouhieddine TH, Dai X, Kluegel L, Chen C, Batta K, Furer N, Vedula RS, Beaulaurier J, Drong AW, Hickey S, Dusaj N, Mullokandov G, Stasiw AM, Su J, Chaligné R, Juul S, Harrington E, Knowles DA, Potenski CJ, Wiseman DH, Tanay A, Shlush L, Lindsley RC, Ghobrial IM, Taylor J, Abdel-Wahab O, Gaiti F, Landau DA. Cortés-López M, et al. Among authors: vedula rs. Cell Stem Cell. 2023 Sep 7;30(9):1262-1281.e8. doi: 10.1016/j.stem.2023.07.012. Epub 2023 Aug 14. Cell Stem Cell. 2023. PMID: 37582363
Complementary medicine.
Vedula RS, Britt G, Kopelman RI, Rencic J. Vedula RS, et al. J Gen Intern Med. 2014 Feb;29(2):412-6. doi: 10.1007/s11606-013-2636-5. Epub 2013 Oct 3. J Gen Intern Med. 2014. PMID: 24197631 Free PMC article. No abstract available.
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation.
Chen S, Vedula RS, Cuevas-Navarro A, Lu B, Hogg SJ, Wang E, Benbarche S, Knorr K, Kim WJ, Stanley RF, Cho H, Erickson C, Singer M, Cui D, Tittley S, Durham BH, Pavletich TS, Fiala E, Walsh MF, Inoue D, Monette S, Taylor J, Rosen N, McCormick F, Lindsley RC, Castel P, Abdel-Wahab O. Chen S, et al. Among authors: vedula rs. Cancer Discov. 2022 Oct 5;12(10):2434-2453. doi: 10.1158/2159-8290.CD-21-1631. Cancer Discov. 2022. PMID: 35904492 Free PMC article.
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
Lane AA, Garcia JS, Raulston EG, Garzon JL, Galinsky I, Baxter EW, Leonard R, DeAngelo DJ, Luskin MR, Reilly CR, Stahl M, Stone RM, Vedula RS, Wadleigh MM, Winer ES, Mughal T, Brooks C, Gupta IV, Stevenson KE, Neuberg DS, Ren S, Keating J, Konopleva M, Stein A, Pemmaraju N. Lane AA, et al. Among authors: vedula rs. Blood Adv. 2024 Feb 13;8(3):591-602. doi: 10.1182/bloodadvances.2023011721. Blood Adv. 2024. PMID: 38052038 Free PMC article. Clinical Trial.
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy.
Versluis J, Pandey M, Flamand Y, Haydu JE, Belizaire R, Faber M, Vedula RS, Charles A, Copson KM, Shimony S, Rozental A, Bendapudi PK, Wolach O, Griffiths EA, Thompson JE, Stone RM, DeAngelo DJ, Neuberg D, Luskin MR, Wang ES, Lindsley RC. Versluis J, et al. Among authors: vedula rs. Blood Adv. 2022 May 10;6(9):2835-2846. doi: 10.1182/bloodadvances.2021006166. Blood Adv. 2022. PMID: 35081257 Free PMC article.
BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes.
Schaefer EJ, Wang HC, Karp HQ, Meyer CA, Cejas P, Gearhart MD, Adelman ER, Fares I, Apffel A, Lim K, Xie Y, Gibson CJ, Schenone M, Murdock HM, Wang ES, Gondek LP, Carroll MP, Vedula RS, Winer ES, Garcia JS, Stone RM, Luskin MR, Carr SA, Long HW, Bardwell VJ, Figueroa ME, Lindsley RC. Schaefer EJ, et al. Among authors: vedula rs. Blood Cancer Discov. 2022 Mar 1;3(2):116-135. doi: 10.1158/2643-3230.BCD-21-0115. Blood Cancer Discov. 2022. PMID: 35015684 Free PMC article.
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
Chen EC, Liu Y, Harris CE, Winer ES, Wadleigh M, Lane AA, Vedula RS, Lindsley RC, Copson KM, Charles A, Marty F, Neuberg D, DeAngelo DJ, Stone RM, Luskin MR, Issa NC, Garcia JS. Chen EC, et al. Among authors: vedula rs. Leuk Lymphoma. 2022 Aug;63(8):1934-1941. doi: 10.1080/10428194.2022.2047964. Epub 2022 Mar 15. Leuk Lymphoma. 2022. PMID: 35289704 Free PMC article.
12 results